The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

During his time in Columbus, Dr. Miller published an illustrated book, “Principles of Health Preservation”, which observed ...

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

A significant proportion of patients do not consult a physician for this condition. Early diagnosis is essential in order to implement management strategies that have excellent efficacy rates and ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...

Sinusitis can cause facial pressure, sinus headache, and other symptoms. Treatment may depend on the cause. A sinus infection, also known as sinusitis or rhinosinusitis, occurs when your nasal ...

COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...